K. Bakken

发表

Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.

J. Sarkaria, W. Elmquist, J. Pokorny, 2013 .

Single-cell based elucidation of molecularly-distinct glioblastoma states and drug sensitivity

Evan O. Paull, Mariano J. Alvarez, J. Sarkaria, 2019, bioRxiv.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma

J. Sarkaria, Minjee Kim, Shuangling Zhang, 2017, The Journal of Pharmacology and Experimental Therapeutics.

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

J. Sarkaria, B. Ma, J. Eckel-Passow, 2015, Clinical Cancer Research.

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

J. Sarkaria, F. Boakye-Agyeman, J. Reid, 2014, Clinical Cancer Research.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

R. Verhaak, J. Sarkaria, F. Boakye-Agyeman, 2015, Journal of the National Cancer Institute.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks

J. Sarkaria, Liewei Wang, F. White, 2020, Cancer Research.

Preclinical modeling in GBM PDX xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules.

J. Sarkaria, H. Lane, J. Eckel-Passow, 2021, Neuro-oncology.

Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model

J. Sarkaria, W. Elmquist, J. Pokorny, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Efflux transporters at the blood-brain barrier limit delivery and efficacy of CDK4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model

J. Sarkaria, W. Elmquist, J. Pokorny, 2015 .

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

J. Sarkaria, P. Decker, Ying Feng, 2017, Molecular Cancer Therapeutics.

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma

Rebecca S. Lescarbeau, J. Sarkaria, P. Canoll, 2016, Molecular Cancer Therapeutics.

Quantitative Phosphoproteomics Reveals Wee 1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma Citation

Rebecca S. Lescarbeau, J. Sarkaria, P. Canoll, 2016 .

RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.

J. Sarkaria, J. Eckel-Passow, P. Decker, 2022, Neuro-Oncology.

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

J. Sarkaria, P. Decker, Minjee Kim, 2021, Molecular Cancer Therapeutics.

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

J. Sarkaria, F. White, J. Eckel-Passow, 2021, Neuro-oncology.

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models

J. Sarkaria, N. Agar, P. Decker, 2023, Neuro-oncology advances.

Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma

J. Sarkaria, E. Galanis, J. Ecsedy, 2016, Journal of Neuro-Oncology.

The Impact of Hemi-brain Irradiation on Accumulation of PI3K/mTOR Inhibitors With Limited (GDC-0980) and Robust (GNE-317) Blood–Brain Barrier Penetration

J. Sarkaria, T. Sio, K. Furutani, 2014 .

Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization

J. Sarkaria, B. Harley, W. Elmquist, 2024, Science Translational Medicine.

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

J. Sarkaria, F. Boakye-Agyeman, J. Reid, 2014, Clinical Cancer Research.